Cargando…
Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285685/ https://www.ncbi.nlm.nih.gov/pubmed/34559450 http://dx.doi.org/10.1111/obr.13358 |
_version_ | 1784747836295872512 |
---|---|
author | Barone, Ines Caruso, Amanda Gelsomino, Luca Giordano, Cinzia Bonofiglio, Daniela Catalano, Stefania Andò, Sebastiano |
author_facet | Barone, Ines Caruso, Amanda Gelsomino, Luca Giordano, Cinzia Bonofiglio, Daniela Catalano, Stefania Andò, Sebastiano |
author_sort | Barone, Ines |
collection | PubMed |
description | The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body adiposity on breast cancer onset and progression. However, an emerging but overlooked issue of clinical significance is the limited efficacy of the conventional endocrine therapies with selective estrogen receptor modulators (SERMs) or degraders (SERDs) and aromatase inhibitors (AIs) in patients affected by breast cancer and obesity. The mechanisms behind the interplay between obesity and endocrine therapy resistance are likely to be multifactorial. Therefore, what have we actually learned during these years and which are the main challenges in the field? In this review, we will critically discuss the epidemiological evidence linking obesity to endocrine therapeutic responses and we will outline the molecular players involved in this harmful connection. Given the escalating global epidemic of obesity, advances in understanding this critical node will offer new precision medicine‐based therapeutic interventions and more appropriate dosing schedule for treating patients affected by obesity and with breast tumors resistant to endocrine therapies. [Image: see text] |
format | Online Article Text |
id | pubmed-9285685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92856852022-07-18 Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives Barone, Ines Caruso, Amanda Gelsomino, Luca Giordano, Cinzia Bonofiglio, Daniela Catalano, Stefania Andò, Sebastiano Obes Rev Obesity Comorbidity/Etiology and Pathophysiology The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body adiposity on breast cancer onset and progression. However, an emerging but overlooked issue of clinical significance is the limited efficacy of the conventional endocrine therapies with selective estrogen receptor modulators (SERMs) or degraders (SERDs) and aromatase inhibitors (AIs) in patients affected by breast cancer and obesity. The mechanisms behind the interplay between obesity and endocrine therapy resistance are likely to be multifactorial. Therefore, what have we actually learned during these years and which are the main challenges in the field? In this review, we will critically discuss the epidemiological evidence linking obesity to endocrine therapeutic responses and we will outline the molecular players involved in this harmful connection. Given the escalating global epidemic of obesity, advances in understanding this critical node will offer new precision medicine‐based therapeutic interventions and more appropriate dosing schedule for treating patients affected by obesity and with breast tumors resistant to endocrine therapies. [Image: see text] John Wiley and Sons Inc. 2021-09-24 2022-02 /pmc/articles/PMC9285685/ /pubmed/34559450 http://dx.doi.org/10.1111/obr.13358 Text en © 2021 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Obesity Comorbidity/Etiology and Pathophysiology Barone, Ines Caruso, Amanda Gelsomino, Luca Giordano, Cinzia Bonofiglio, Daniela Catalano, Stefania Andò, Sebastiano Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives |
title | Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives |
title_full | Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives |
title_fullStr | Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives |
title_full_unstemmed | Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives |
title_short | Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives |
title_sort | obesity and endocrine therapy resistance in breast cancer: mechanistic insights and perspectives |
topic | Obesity Comorbidity/Etiology and Pathophysiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285685/ https://www.ncbi.nlm.nih.gov/pubmed/34559450 http://dx.doi.org/10.1111/obr.13358 |
work_keys_str_mv | AT baroneines obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives AT carusoamanda obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives AT gelsominoluca obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives AT giordanocinzia obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives AT bonofigliodaniela obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives AT catalanostefania obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives AT andosebastiano obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives |